Knightpoint Group LLC
Proprietary Inhalation Platform. Integrated Combination Products.
Knightpoint Group develops and commercializes combination products that integrate advanced drug formulations with next-generation delivery technology.
Integrated Capabilities
We control the entire system - from device design to drug formulation to manufacturing - delivering integrated combination products.
Proprietary Platform
The Mirai™ inhaler - a patented device (granted in the US and 38 European countries), low-resistance, designed for patient compliance and broad therapeutic application.
- Device patents granted (US + 38 EU countries)
- Low resistance for all patients
- Modern, pocket-sized design
Formulation Science
In-house expertise in complex respiratory formulations, including triple-combination ICS/LAMA/LABA products.
- Triple-combination expertise
- In-house triple-combination formulation expertise
- Broad API sourcing
Combination Products
FDA combination product pathway - integrated drug + device products manufactured through our global partnership.
- Global manufacturing partner
- End-to-end control
- Designed to lower patient cost
Why Integrated Control Matters
Most companies are either device specialists or formulation experts - rarely both. Knightpoint Group controls the entire process, enabling optimized product performance and faster development timelines.
Optimized System Performance
Device and formulation designed together, not independently.
Accelerated Development
No waiting on external partners for critical decisions.
Protected IP
Device patents granted in the US and 38 European countries.
The Mirai™ Advantage
Global Design
One patented platform - granted across US + 38 EU markets
Resistance
Cost
Partnership Opportunities
We're actively exploring strategic partnerships, licensing opportunities, and business development discussions.